Drug Database · Clinicians

Lacidipine

Brands (3) Lacibloc, Lacipil, CalcipineShow all

Calcium channel blocker (dihydropyridine derivatives); Selective calcium channel blockers with mainly vascular effect (dihydropyridine derivative PH FDA category

Rx · Prescription drug6 PH productsVAT-exempt (some products) Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Contraindications

  • Severe aortic stenosis
  • Hypersensitivity (caution with prior dihydropyridine allergy)
renalcarematters.com, reviewed

Dosing: Adult

  • Hypertension: 2 mg once daily in the morning; increase to 4 mg and then 6 mg after 3 to 4 weeks on each dose if needed
renalcarematters.com, reviewed

Dosing: Altered kidney function

Lacidipine is a dihydropyridine calcium-channel blocker metabolized by the liver (CYP3A4) and excreted mainly in feces as metabolites. The Dutch label needs no kidney dose adjustment because it is not renally excreted. It has no US FDA label.

Kidney function measure: SmPC sets no kidney adjustment; bands shown on creatinine clearance (CrCl).

Show full dosing details
CrCl ≥60 mL/min
Usual: 2 mg once daily in the morning; increase to 4 mg, then 6 mg, after at least 3 to 4 weeks on each dose (SmPC).
CrCl 30–59 mL/min
No dose adjustment: lacidipine is not excreted by the kidneys (SmPC).
CrCl 15–29 mL/min
No dose adjustment: lacidipine is not excreted by the kidneys (SmPC).
CrCl <15 mL/min (not on dialysis)
No dose adjustment: lacidipine is not excreted by the kidneys (SmPC).
Hemodialysis (intermittent)
No kidney adjustment (not renally excreted); no dialysis data in the SmPC. Highly protein-bound, so dialysis removal is unlikely.
Peritoneal dialysis
No kidney adjustment; no PD data.
CRRT
No data.
  • Dialyzable? Not stated (over 95% protein-bound).
  • Monitoring Blood pressure; edema; caution with conduction disease, QT prolongation and reduced cardiac reserve; avoid grapefruit (SmPC 4.4, 4.5).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: CBG-MEB (Netherlands) product information (December 22, 2022). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Not recommended under 18 years (SmPC).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Film-coated tablet: 2 mg, 4 mg, 6 mg
  • Tablet: 6 mg

Registered products in the Philippines

6 products registered with the Food and Drug Administration (FDA) Philippines list Lacidipine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Lacipidine (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products6
Philippine FDA-registered products for Lacidipine
Package insert
CalcipineLacidipine
4mg Film-Coated TabletAlu/Alu Blister Pack x 8's Box of 24's
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc.
DRP-9545
Jan 29, 2029
LaciblocLacidipine
4 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's)
RxVAT-exempt
LLOYD LABORATORIES INC.Philippines
TGP-PHARMA INC.Trader: EUROHEALTH CARE EXPONENTS,INC.
DRP-9545-01
Jan 29, 2029
LaciblocLacidipine
6 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: Ultramed Pharma, Inc.
DR-XY38934
Jan 11, 2031
LacipilLacipidineVariant spelling
2 mg Film-Coated TabletChild-Resistant Aluminum Foil Blister Pack x 7's (Box of 28's)
Rx
GLAXO WELLCOME S.A.Spain
Importer: GLAXOSMITHKLINE PHILIPPINES, INC.
DR-XY16826
Aug 18, 2028
LacipilLacidipine
6 mg TabletChild-Resistant Aluminum Foil Blister Pack x 7's (Box of 28's)
RxVAT-exempt
GLAXO WELLCOME S.A.Spain
GLAXOSMITHKLINE PHILIPPINES, INC.
DR-XY29222
Dec 4, 2028
UnbrandedLacidipine
6 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's)
RxVAT-exempt
Lloyd Laboratories, Inc.Bulacan
—
DRP-10490
Oct 5, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Strong CYP3A4 inhibitors or inducers (itraconazole, rifampicin), cimetidineAdjust or monitorAltered lacidipine levels.Monitor blood pressure.
Grapefruit juiceAvoidAltered bioavailability.Avoid.
Other antihypertensives, alcoholMinorAdditive blood-pressure lowering.Monitor.
Corticosteroids, tetracosactideMinorLess antihypertensive effect.Monitor.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Headache, dizziness
  • Palpitations, tachycardia, flushing
  • Edema, asthenia
  • Nausea, rash, polyuria
  • Raised alkaline phosphatase

Serious

  • Worsening angina (caution in unstable angina and after recent myocardial infarction)
renalcarematters.com, reviewed

Monitoring parameters

  • Blood pressure; edema; caution with conduction disease, QT prolongation and reduced cardiac reserve; avoid grapefruit (SmPC 4.4, 4.5). Kidney
  • Blood pressure
  • Edema
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

BioavailabilityAbout 10% (high first pass)
Time to peak30 to 150 minutes
Half-life13 to 19 hours (steady state)
Protein bindingOver 95%
Metabolism (CYP, transporters)Hepatic, mainly CYP3A4 (inactive metabolites)
Renal excretion kidneyAbout 70% as metabolites in feces; remainder in urine (not as parent)
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Medicines Evaluation Board (CBG-MEB), Netherlands. Lacidipine Teva 2 mg/4 mg film-coated tablets SmPC (RVG 105980) [CBG-MEB (Netherlands) product information, December 22, 2022; no US FDA label]. https://www.geneesmiddeleninformatiebank.nl/smpc/h105980_smpc.pdf
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Teva Nederland BV. (2022). Lacidipine 2 mg and 4 mg Teva, film-coated tablets (RVG 105980/105981) [Summary of product characteristics; text dated December 22, 2022]. College ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board), Netherlands. https://www.geneesmiddeleninformatiebank.nl/smpc/h105980_smpc.pdf

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .